Nivolumab treatment in a patient with BRAF mutant advanced melanoma and liver failure with encephalopathy.
Rumeysa ColakCaner KaparIlkay GulturkMesut YilmazPublished in: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (2023)
In this case is reported patient with hepatic encephalopathy due to an advanced refractory melanome successfully, and safely, treated with programed cell death-1 (PD-1) inhibitors. Clinical trials to explore the benefits of these immunotherapies in the hepatic failure population with advanced solid tumors should be supported.